Standout Papers

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an o... 2021 2026 2022 2024166
  1. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial (2021)
    Assuntina G. Sacco, Ruifeng Chen et al. The Lancet Oncology

Immediate Impact

62 standout
Sub-graph 1 of 23

Citing Papers

Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
New clinical trial design in precision medicine: discovery, development and direction
2024 Standout
1 intermediate paper

Works of Julie Bykowski being referenced

A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
2022
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
2020

Author Peers

Author Last Decade Papers Cites
Julie Bykowski 167 234 151 223 168 43 829
A. L. Pahor 121 304 139 155 187 51 756
Dennis R. Maceri 175 439 165 208 187 47 848
Joseph M. Aulino 170 288 56 114 95 45 691
Curtis Offiah 211 333 102 109 96 31 922
Edward J. Escott 269 300 135 74 105 42 886
Ho-Fai Wong 164 225 201 123 194 28 667
Niranjan Bhandare 73 185 273 210 222 31 908
Rohini N. Nadgir 143 304 107 68 142 41 791
Moon‐Sing Lee 44 214 229 214 202 61 907
Shy‐Chyi Chin 227 368 237 94 203 71 898

All Works

Loading papers...

Rankless by CCL
2026